

DiRocco LUMINA1 ms

1 **Garetosmab, an inhibitor of activin A, reduces heterotopic**  
2 **ossification and flare-ups in adults with fibrodysplasia**  
3 **ossificans progressiva: a randomized, double-blind, placebo-**  
4 **controlled phase 2 trial**

5 **Maja Di Rocco, MD, PhD,<sup>1</sup> Eduardo Forleo-Neto, MD,<sup>2</sup> Robert Pignolo, MD, PhD,<sup>3</sup>**  
6 **Richard Keen, PhD, FRCP,<sup>4</sup> Philippe Orcel, MD, PhD,<sup>5,6</sup> Thomas Funck-Brentano,**  
7 **MD, PhD,<sup>5,6</sup> Christian Roux, MD, PhD,<sup>7</sup> Sami Kolta, MD,<sup>7</sup> Annalisa Madeo, MD,<sup>1</sup>**  
8 **Judith S Bubbear, MD, FRCP,<sup>4</sup> Jacek Tabarkiewicz, MD, PhD,<sup>8</sup> Małgorzata**  
9 **Szczepanek, MD, PhD,<sup>8</sup> Javier Bachiller-Corral, MD,<sup>9</sup> Angela M Cheung, MD,**  
10 **PhD,<sup>10</sup> Kathryn M Dahir, MD,<sup>11</sup> Esmée Botman, MD, PhD,<sup>12</sup> Pieter G Raijmakers,**  
11 **MD, PhD,<sup>13</sup> Mona Al Mukaddam, MD,<sup>14</sup> Lianne Tile, MD,<sup>10</sup> Cynthia Portal-Celhay,**  
12 **MD, PhD,<sup>2</sup> Neena Sarkar, PhD,<sup>2</sup> Peijie Hou, PhD,<sup>2</sup> Bret Musser, PhD,<sup>2</sup> Anita**  
13 **Boyapati, PhD,<sup>2</sup> Kusha Mohammadi, PhD,<sup>2</sup> Scott Mellis, MD, PhD,<sup>2</sup> Andrew J.**  
14 **Rankin, PhD,<sup>2</sup> Aris N. Economides, PhD,<sup>2</sup> Dinko Gonzalez Trotter, PhD,<sup>2</sup> Gary**  
15 **Herman, MD,<sup>2</sup> Sarah J. O'Meara, PhD,<sup>2</sup> Richard DeIGizzi, MS,<sup>2</sup> David M. Weinreich,**  
16 **MD,<sup>2</sup> George D. Yancopolous, MD, PhD,<sup>2</sup> E. Marelise W. Eekhoff, MD, PhD,<sup>12\*</sup>**  
17 **Frederick S. Kaplan, MD,<sup>14\*</sup> on behalf of the LUMINA-1 Investigators**

18 \*Co-senior authors: EMWE, Lead Clinical Principal Investigator; FSK, Global Principal  
19 Investigator.

20 *<sup>1</sup>Department of Pediatrics, Unit of Rare Diseases, IRCCS Istituto Giannina Gaslini,*  
21 *Genoa, Italy; <sup>2</sup>Regeneron Pharmaceuticals, Tarrytown, NY, USA; <sup>3</sup>Department of*

DiRocco LUMINA1 ms

22 *Medicine, Mayo Clinic, Rochester, MN, USA;* <sup>4</sup>*Centre for Metabolic Bone Disease Royal*  
23 *National Orthopaedic Hospital NHS Trust, London, UK;* <sup>5</sup>*Department of Rheumatology-*  
24 *DMU Locomotion, Assistance Publique - Hôpitaux de Paris, Paris, France;* <sup>6</sup>*INSERM*  
25 *Université Paris Cité, Paris, France;* <sup>7</sup>*Department of Rheumatology, Cochin Hospital,*  
26 *Assistance Publique - Hôpitaux de Paris, Paris, France;* <sup>8</sup>*Institute of Medical Sciences,*  
27 *Medical College of Rzeszów University, Rzeszów University, Rzeszów, Podkarpackie,*  
28 *Poland;* <sup>9</sup>*Department of Rheumatology, Hospital Universitario Ramón y Cajal, Madrid,*  
29 *Spain;* <sup>10</sup>*University Health Network, University of Toronto, Toronto, ON, Canada;*  
30 <sup>11</sup>*Vanderbilt University Medical Center, Program for Metabolic Bone Disorders,*  
31 *Nashville, TN, USA;* <sup>12</sup>*Department of Internal Medicine Section of Endocrinology,*  
32 *Amsterdam UMC, Vrije Universiteit, Amsterdam Bone Center, Amsterdam, The*  
33 *Netherlands;* <sup>13</sup>*Department of Radiology and Nuclear Medicine , Amsterdam UMC, Vrije*  
34 *Universiteit, Amsterdam, The Netherlands;* <sup>14</sup>*Departments of Orthopaedics, Medicine*  
35 *and the Center for Research in FOP & Related Disorders, University of Pennsylvania*  
36 *Perelman School of Medicine, Philadelphia, PA, USA.*

DiRocco LUMINA1 ms

## 37 **ABSTRACT**

### 38 **Background**

39 Fibrodysplasia ossificans progressiva (FOP), an ultra-rare disorder caused by mutations  
40 in the gene encoding activin A receptor type 1 (*ACVR1*), is characterized by painful  
41 flare-ups and cumulative heterotopic ossification (HO). Garetosmab, a fully-human  
42 monoclonal antibody blocking activin A, prevents HO in FOP mice.

### 43 **Methods**

44 LUMINA-1 (NCT03188666) was a phase 2 , multi-center, randomized, double-blind,  
45 placebo-controlled study evaluating the safety, tolerability, and effects on HO of  
46 intravenous (IV) garetosmab 10 mg/kg every 4 weeks (Q4W). Adult patients with FOP  
47 were randomized to garetosmab or placebo for 28 weeks (Period\_1), followed by an  
48 open-label period (Period\_2). After Period\_2, patients were allowed to stay on  
49 garetosmab in an open-label extension. For Period\_1, primary endpoints were HO total  
50 lesion activity (HO-TLA) by <sup>18</sup>F-sodium fluoride positron emission tomography (<sup>18</sup>F-NaF  
51 PET) and HO total lesion volume by computed tomography (CT). The Period\_2 primary  
52 endpoint compared the number of new lesions in Period\_2 versus Period\_1. The safety  
53 primary endpoint was incidence and severity of TEAEs through the end of the Period 1  
54 at week 28.

### 55 **Findings**

56 Patients (n=44) were randomized to garetosmab (n=20) or placebo (n=24). In Period\_1,  
57 there was a trend for garetosmab to decrease HO-TLA versus placebo (24.6%; *P*=0.07),

DiRocco LUMINA1 ms

58 primarily driven by near complete prevention of new lesions (97% decrease by  $^{18}\text{F}$ -NaF  
59 PET, post-hoc  $P=0.009$ ; 90% relative reduction by CT, post-hoc  $P=0.017$ ); flare-ups  
60 were significantly reduced ( $P=0.0005$ ). For placebo patients transitioning to garetosmab  
61 in Period\_2, no patients developed new HO lesions (0% in Period\_2 versus 40.9% in  
62 Period\_1;  $P=0.0027$ ) by CT. All 44 patients met primary safety endpoint of at least one  
63 TEAE during Period 1. Garetosmab was associated with more adverse events than  
64 placebo: mild recurrent epistaxis, madarosis, and skin/soft tissue infections. Overall, the  
65 AEs were predominantly mild in severity, with no effect on patients' ability to receive  
66 garetosmab. Five deaths (5/44; 11.4%) occurred either in Period\_2 or the open-label  
67 extension. The deaths were associated with baseline disease severity in some,  
68 preexisting comorbidities in others and occurred following 8-16 doses (median: 15) of  
69 garetosmab in the open label/follow-up periods.

## 70 **Interpretation**

71 Garetosmab reduced flare-ups and prevented new HO lesions in FOP patients.  
72 Although side effects were mild to moderate, there were a relatively high number of  
73 deaths for a small study; the deaths were not related to epistaxis and considered  
74 unlikely to be related to garetosmab.

75 **Funding:** Regeneron Pharmaceuticals, Inc.

DiRocco LUMINA1 ms

## 76 **Introduction**

77 Fibrodysplasia ossificans progressiva (FOP; MIM#135100) is an ultra-rare, autosomal  
78 dominant disorder<sup>1</sup> with an estimated prevalence of 0.36–1.36 per million.<sup>2-5</sup> The most  
79 common and debilitating manifestation of FOP is the heterotopic ossification (HO) of  
80 connective tissues, such as tendons, ligaments, and skeletal muscles excepting the  
81 diaphragm, extraocular muscles and the tongue.<sup>6</sup> HO typically presents during the first  
82 decade of life and may be accompanied by painful, soft tissue inflammatory swellings,  
83 known as flare-ups, however, this feature of the disease is variable.<sup>7</sup> A diagnostic  
84 hallmark of FOP at birth is bilateral malformation of the great toes, which is often missed  
85 and can lead to a delay in diagnosis.<sup>8</sup>

86 HO in FOP is seemingly episodic, and may be precipitated by trauma.<sup>9</sup> The  
87 resulting HO lesions accumulate, leading to joint immobility, skeletal deformity, severe  
88 pain, disability, and early mortality.<sup>6,10,11</sup> Patients with FOP experience significant  
89 disease burden including restriction of activity as well as hearing loss which worsens  
90 social isolation leading to decreased quality of life. Surgical removal of bone is  
91 ineffective as it causes new HO and is associated with high anesthetic challenges.<sup>12</sup>  
92 The degree of immobility can be captured by the cumulative analog joint involvement  
93 scale (CAJIS) score, measuring mobility across 15 anatomic locations, and ranging  
94 from 0 to 30 (higher scores indicating more severe limitations in mobility and other  
95 function).<sup>13</sup> On the basis of FOP features related to joint dysfunction (flare-up activity,  
96 body regions affected, thoracic insufficiency, and other complications) as well as its  
97 consequences (assistance in activities of daily living, ambulation, and CAJIS score), 5  
98 clinical stages of FOP have been defined: early, moderate, severe, profound, and end

DiRocco LUMINA1 ms

99 of life.<sup>14</sup> Estimated median age of survival for patients with FOP is 56 years.<sup>15</sup> Mortality  
100 is correlated with disease severity and CAJIS score and is primarily due to  
101 cardiorespiratory failure from thoracic insufficiency syndrome, pneumonia, and  
102 complications of falls.<sup>15</sup> With no globally-approved disease-modifying therapies, clinical  
103 management is mostly limited to symptomatic flare-up treatment with corticosteroids or  
104 non-steroidal anti-inflammatory agents, evidence of which is anecdotal.<sup>7</sup>

105 FOP is caused by heterozygous missense mutations in *ACVR1*, the gene encoding  
106 activin A receptor type 1, a bone morphogenetic protein (BMP) type I receptor.<sup>16</sup> A  
107 significant breakthrough in understanding the molecular mechanism of HO in FOP was  
108 the discovery that FOP-causing variants of *ACVR1* recognize activin A as an agonist  
109 (**Figure S1**).<sup>17-20</sup> In contrast, activin A normally inhibits BMP signalling via wild-type  
110 *ACVR1*.<sup>17,21</sup> Garetosmab, a fully-human monoclonal antibody (generated using  
111 *VelocImmune™ technology*),<sup>1,2</sup> binds activin A and blocks its ability to activate FOP-  
112 mutant *ACVR1*. Inhibition of activin A with garetosmab blocked new HO lesions and  
113 resulted in stasis or partial reduction in the volume of pre-existing lesions in a  
114 genetically humanized murine FOP model in which FOP-mutant *ACVR1* was  
115 introduced.<sup>17,18</sup> As such, it was hypothesized that garetosmab may beneficially impact  
116 FOP disease progression in humans. LUMINA-1 was designed to assess the safety and  
117 efficacy of garetosmab as a potential disease-modifying treatment for FOP, and  
118 consequently also validate the role of activin A as a key driver of HO in FOP.

DiRocco LUMINA1 ms

## 119 **Methods**

### 120 **Study design**

121 LUMINA-1 (NCT03188666) was a phase 2, randomized, double-blind, placebo-  
122 controlled study evaluating the safety, tolerability, and effects on HO of intravenous (IV)  
123 garetosmab 10 mg/kg every 4 weeks (Q4W). The study was conducted at 11 sites in 8  
124 countries across North America and Europe, between February 26, 2018 and  
125 September 16, 2021. <sup>18</sup>F-NaF PET and whole-body, low-dose X-ray computed  
126 tomography (CT)<sup>22</sup> were used to measure and track HO. The study consisted of a 28-  
127 day screening/baseline period followed by a 28-week randomized, double-blind,  
128 placebo-controlled period (Period\_1), a 28-week open-label treatment period  
129 (Period\_2), and a subsequent open-label extension from week 56 to end of study  
130 (**Figure S2**). The primary analysis was conducted when all patients completed  
131 Period\_1. Further analyses were conducted at the end of Period\_2. Amendments to the  
132 trial protocol are detailed in **Table S1**. Patient safety and welfare were monitored by an  
133 Independent Data Monitoring Committee. This study was conducted in accordance with  
134 the 2013 Declaration of Helsinki and the International Council for Harmonization  
135 guidelines for GCP. All patients provided written, informed consent. Detailed information  
136 and a full list of the Institutional Review Boards are in the **Supplementary Methods**.

### 137 **Patients**

138 Adult patients (aged 18–60 years) with a clinical diagnosis of FOP (based on congenital  
139 great toe malformation, episodic soft tissue swelling, and/or progressive HO) were  
140 included. Clinical diagnosis was confirmed with documentation of any FOP-causing

DiRocco LUMINA1 ms

141 *ACVR1* variant and disease activity (defined as pain, swelling, stiffness, and other  
142 signs/symptoms associated with FOP flare-ups; or worsening of joint function, or  
143 radiographic progression of HO) within 1 year of screening. Key inclusion/exclusion  
144 criteria are in **Table S2** and **Supplementary Methods**.

#### 145 **Randomization and masking**

146 Enrolled patients were randomized (1:1) to receive garetosmab 10 mg/kg Q4W as  
147 previously assessed,<sup>23</sup> or placebo in Period\_1, according to a central randomization  
148 scheme. Block randomization was done using an interactive response technology (IRT)  
149 provided to the designated study pharmacist or qualified designee. Randomization was  
150 stratified by presence/absence of baseline active HO lesions, gender, and mutation  
151 type. All PET/CT scans were reviewed by 2 independent readers and an adjudicator; all  
152 3 were blinded to treatment assignment.

#### 153 **Procedures**

154 Patients were assigned to receive garetosmab 10 mg/kg or placebo Q4W for 28 weeks  
155 (Period\_1). After week 28, all patients continued or were switched to receive  
156 garetosmab 10 mg/kg Q4W (Period\_2). At the conclusion of Period\_2, patients were  
157 given the option to continue on garetosmab in an open-label extension. Whole-body  
158 PET/CT scans were acquired to identify pre-existing target lesions at baseline, identify  
159 new HO lesions, and measure volume changes in pre-existing target and new HO  
160 lesions. Baseline imaging with PET/CT was performed at most 7 days prior to study  
161 drug administration and at Weeks 8, 28, 56, and 76 (**Figure S2**). Detailed information  
162 on imaging acquisition and read procedures are in the **Supplementary Methods**.



DiRocco LUMINA1 ms

## 163 **Outcomes**

164 Period\_1: The pre-specified primary endpoint for efficacy was the effect of garetosmab  
165 versus placebo on time-weighted average (TWA) of the percentage change from  
166 baseline in total lesion activity (TLA) by PET; TLA is considered proportional to the  
167 deposition rate of bone mineral into actively forming HO lesions (definition in  
168 supplementary methods section). The next endpoint in the hierarchy was to assess  
169 percentage change of the total volume of HO lesions by CT in Period\_1 relative to  
170 baseline. Other key secondary and exploratory endpoints are listed in **Table S3**.  
171 Exploratory endpoints in Period\_1 included the percentage of patients with flare-ups as  
172 assessed by patient diary and investigator report.

173 Period\_2: Based on the outcomes of Period\_1 (see Results), the primary endpoint for  
174 efficacy for Period\_2 was prospectively changed to the number of new lesions in  
175 patients transitioning from placebo to garetosmab as assessed by CT.

176 Safety: The primary safety endpoint for Period\_1 and a primary endpoint for Period\_2  
177 was the incidence and severity of adverse events, which included those not present at  
178 baseline or an exacerbation of a pre-existing condition.

## 179 **Statistical analyses**

180 Testing of primary and key secondary efficacy outcomes followed a pre-specified  
181 hierarchical testing procedure to address multiplicity at an overall 2-sided  $\alpha=0.05$   
182 significance for Period\_1. Other secondary outcomes were tested at the nominal 2-  
183 sided  $\alpha=0.05$  significance without multiplicity adjustment. In Period\_2, a 2-sided  
184 10% significant level was applied for the primary and key secondary endpoints. For the

DiRocco LUMINA1 ms

185 Period\_1 primary analysis, the TWA percent change from baseline in TLA <sup>18</sup>F-NaF PET  
186 over 28 weeks was analyzed in AHO (baseline active HO analysis set) and AHOC  
187 (baseline active HO classic ACVR1[R206H] mutation analysis set) populations using an  
188 analysis of covariance model. The difference in least squares mean change from  
189 baseline, 95% confidence interval, and *P*-value were provided from the model to  
190 compare garetosmab against placebo group. For Period\_2 primary analysis, the  
191 Wilcoxon signed-rank test was used to compare the number of new HO lesions as  
192 assessed by CT at week 56 (relative to week 28 scan) with the number of new HO  
193 lesions at week 28 (relative to baseline scan) in patients who crossed over from placebo  
194 to garetosmab. The estimate and 95% confidence interval of the rate of new HO lesions  
195 at week 56 and that of the rate ratio (comparing Period\_2 versus Period\_1) were based  
196 on a negative binomial model with repeated measures and using a generalized  
197 estimating equation. Safety outcomes were analyzed using descriptive statistics.  
198 Further details are provided in the **Supplementary Methods** and amendments to the  
199 statistical methodology are summarized in **Table S1**.

DiRocco LUMINA1 ms

## 200 **Results**

201 LUMINA-1 enrolled 44 patients with FOP, all of whom had active HO (AHO) at baseline  
202 (see full definition in the **Supplementary Methods**). Overall, 42/44 (95.5%) of patients  
203 had the “classic” FOP-causing variant of *ACVR1* (c.617G>A, p.R206H) (AHOC  
204 population). Patients were randomized to garetosmab 10 mg/kg IV Q4W (n=20) or  
205 placebo (n=24) (**Figure S2; Figure S3**). Baseline demographics and disease  
206 characteristics were similar between groups (**Table S4**). The mean (SD) age was 27.6  
207 (8.5) years. The mean CAJIS score at baseline was 15.7 (SD: 6.6; range, 6–30; Median  
208 [Quartile1, Quartile3]: 15.0 [11, 19]). Data analyses presented are for the AHO  
209 population and were similar to the AHOC population (**Table S5A**). The study was  
210 initiated in February 2018; primary data cut-off was September 17, 2019 (week 28);  
211 additional data cut-off dates for efficacy analyses were August 11, 2020 (week 56), and  
212 October 30, 2020 (week 76); safety was reported until last patient last visit on  
213 September 16, 2021.

### 214 **Period\_1 Results**

215 Forty-three (98%) patients completed Period\_1. During Period\_1, garetosmab reduced  
216 TLA (new and existing lesions) from baseline versus placebo by 24.6% (95%  
217 confidence interval [CI]: -51.8%–2.5%;  $P=0.07$ ; **Figure 1A; Supplementary Section:**  
218 **Results**). Although this did not meet the pre-specified statistical threshold of  $P\leq 0.05$ ,  
219 patients treated with garetosmab had a ~97% relative reduction in new lesion activity, a  
220 ~90% relative reduction in new HO lesion volume compared with the placebo arm  
221 (**Figure 1B,C; Table S6**). Additionally, a reduction in both the number of new HO

DiRocco LUMINA1 ms

222 lesions per patient as assessed by PET (mean of 0.15 new lesions/patient for  
223 garetosmab versus 1.19 for placebo; post-hoc analysis, nominal  $P=0.006$ ) and CT (0.15  
224 versus 1.13, respectively; post-hoc analysis, nominal  $P=0.009$ ; **Table S6**) were  
225 observed. The total number of new HO lesions in Period\_1 for placebo was 27 by CT  
226 and 29 by PET compared with 3 by CT and PET for garetosmab (**Figure 1B**). The  
227 percentage of patients who developed new lesions in Period\_1 was lower with  
228 garetosmab (15% by CT; 15% by PET) versus placebo (45.8% by CT and PET; nominal  
229  $P=0.05$ ; **Figure S4**).

230 Given that garetosmab appears to block the formation of new HO in patients with  
231 FOP, its effects on normal bone were also examined as reference using PET.  
232 Assessment of percent change from baseline of the mean [standard error] SUVmean of  
233 selected normotopic bones (as defined in the protocol), showed no differences between  
234 treatments at week 8 (garetosmab: 42.0% [9.9]; placebo: 20.3% [9.2]; nominal  $P=0.12$ )  
235 or week 28 (garetosmab: 24.6% [8.4]; placebo: 28.9% [7.7]; nominal  $P=0.71$ ; data not  
236 shown), indicating that garetosmab does not affect bone turnover.

237 In addition to the reduction in the number of new HO lesions, an effect of  
238 garetosmab was also observed on reported flare-ups. A marked reduction was  
239 observed during Period\_1 in patients reporting flare-ups on garetosmab versus placebo  
240 based on patient diary entries (35.0% versus 70.8%, respectively; relative risk  
241 [RR]=0.49; nominal  $P=0.03$ ) and investigator adverse event reports (10.0% versus  
242 41.7%, respectively; RR=0.24; post-hoc analysis, nominal  $P=0.039$ ; **Table 1A; Figure**  
243 **S5A, B**).

DiRocco LUMINA1 ms

244 Since garetosmab's most pronounced effect on HO during Period\_1 was the  
245 suppression of new HO lesions formation, the study hypothesis for Period\_2 was  
246 redefined to be that garetosmab prevents formation of new HO lesions.

### 247 **Period\_2 Results**

248 Of the 43 patients who completed Period\_1, all entered Period\_2 and 42 patients  
249 completed Period\_2. Patients randomized in Period\_1 to placebo crossed-over to  
250 receive garetosmab. In Period\_2, the total number of new lesions measured by CT for  
251 patients who crossed over from placebo to garetosmab was reduced 100% relative to  
252 Period\_1, (0 versus 22, respectively;  $P=0.0039$ ) and 95% by PET (1 versus 23,  
253 respectively;  $P=0.0039$ ; **Figure 2A, B; Table S5B**). Mean new lesion volume and  
254 activity were significantly lower for Period\_2 versus Period\_1 (volume:  $0.05 \text{ cm}^3$  versus  
255  $9.29 \text{ cm}^3$ , respectively,  $P=0.0039$ ; activity: 13.20 versus 204.45, respectively;  $P=0.0273$ ;  
256 **Figure 2C, D**). This reduction was also reflected in the percentage of patients who  
257 developed new lesions, which was significantly lower during Period\_2 compared with  
258 Period\_1 by CT (0% versus 40.9%, respectively;  $P=0.0027$ ) and PET (4.5% versus  
259 40.9%, respectively;  $P=0.0047$ ; **Figure 2E, F**).

260 For patients originally randomized to garetosmab and who remained on garetosmab  
261 in Period\_2, garetosmab's efficacy in preventing new HO lesions was maintained (0  
262 new lesions by CT and PET in Period\_2 versus 2 by CT and 1 by PET in Period\_1;  
263 **Figure S6**. Additionally, the percentage of patients with new lesions was 0% for  
264 Period\_2 by PET and CT (**Figure S6**) for patients remaining on garetosmab.

DiRocco LUMINA1 ms

## 265 **Open-Label Extension Results**

266 During the subsequent open-label extension, 0 new lesions at week 76 were observed  
267 in patients crossing to garetosmab after week 28 (n=17) while one new lesion was  
268 observed by both PET and CT at 76 weeks among patients continuing garetosmab  
269 since baseline (n=15). Overall, treatment with garetosmab resulted in a sustained and  
270 pronounced effect in preventing new HO lesions from forming up to 76 weeks (the time  
271 of last imaging scan assessments in the study). Thirty-four (77%) patients continued in  
272 the study, after the open-label extension.

## 273 **Flare-Ups and CAJIS**

274 For patients switching to garetosmab after week 28, the proportion with new flare-ups  
275 was significantly lower in Period\_2 compared to Period\_1 as reported by both patients  
276 (13.6% versus 68.2%, respectively;  $P=0.0005$ ) and investigators (13.6% versus 45.5%,  
277 respectively;  $P=0.0196$ ; **Table 1B**; **Figure S5C, D**). The total number of new flare-ups  
278 by patient diary was 11 in Period\_2 compared with 31 in Period\_1 and by investigator  
279 report was 4 and 22, respectively (**Figure S5E, F**). The relationship between baseline  
280 age and CAJIS score is depicted in **Figure 3A**.

## 281 **Safety**

282 All patients in the LUMINA-1 trial reported  $\geq 1$  AE during Period\_1 (**Table 2**). One patient  
283 with a medical history of restrictive lung disease, pulmonary congestion, and mucus  
284 plugging discontinued during Period\_1 due to an TEAE of mild pyrexia that followed  
285 recurrent episodes of pneumonia and hemoptysis. Most AEs were considered by  
286 investigators to be mild to moderate in severity. In Period\_1, notable imbalances in AEs

DiRocco LUMINA1 ms

287 with garetosmab versus placebo included epistaxis (50.0% versus 16.7%), madarosis  
288 (loss of eyebrows/eyelashes; 30.0% versus 0%), and a composite of skin and soft  
289 tissue infections that included acne (65% versus 12.5%; **Table S7**; **Table S8**). Nine  
290 serious adverse events (SAEs) in Period\_1 occurred in 6 (13.6%) patients; of these, 4  
291 (20.0%) patients received garetosmab versus 2 (8.3%) patients who received placebo  
292 (**Table S9**). SAEs in the garetosmab group included 3 (15.0%) patients with infections  
293 and infestations, 1 (5.0%) patient with epistaxis (5.0%), and 1 (5.0%) with intestinal  
294 obstruction. The SAE of epistaxis resulted in hospitalization for nasal packing and was  
295 assessed as related to garetosmab by the investigator, but patient required no  
296 transfusions and had no drop in hemoglobin. The patient fully recovered and continued  
297 in the study without recurrence. This SAE of epistaxis led to a protocol amendment to  
298 include additional exclusion criteria (**Table S2**) and baseline (if applicable) and post-  
299 treatment laboratory measures of coagulation parameters and platelet effector function  
300 to exclude patients who may have existing propensity for bleeding or mitigate the  
301 potential risk for epistaxis.

302 Coagulation tests and platelet functional assays including activated prothrombin  
303 time (aPTT), prothrombin time (PTT), and prothrombin international normalized ratio  
304 (INR), measured in a subset of patients at baseline and post treatment, were in the  
305 normal range at baseline and fluctuations observed in placebo or in the garetosmab  
306 treatment group remained within the normal ranges (**Figure S7**). In Period\_1, 13  
307 (65.0%) patients in the garetosmab treatment group experienced a bleeding event  
308 compared to 9 (37.5%) patients in the placebo treatment group (**Table S10**). The only  
309 bleeding event reported in more than two patients in the garetosmab group was

DiRocco LUMINA1 ms

310 epistaxis. Except for the single epistaxis SAE, other events of epistaxis were non-  
311 serious and the majority mild in severity. Other non-epistaxis bleeding events were  
312 balanced between garetosmab and placebo recipients and non-serious. None of the  
313 patients discontinued therapy due to a bleeding AE.

314 All patients reported  $\geq 1$  AE during Period\_2 and subsequent open label extension,  
315 which involved patients receiving garetosmab. The most frequently reported AEs were  
316 consistent with those reported in Period\_1, comprising of skin and soft tissue infections  
317 (81.4%; acne (32.6%), madarosis (46.5%)) and epistaxis (34.9%), and were mostly  
318 mild/moderate in severity (**Table S8; Table S11; Figure 3B and 3C**). During Period\_2  
319 and subsequent treatment until end of study, epistaxis was reported in 15 patients  
320 (34.9%). Most events were mild, and no patients discontinued treatment with  
321 garetosmab due to epistaxis. Twenty SAEs in 13 (30.2%) patients were reported during  
322 Period\_2 until end of study, including infections and infestations (16.3%) and  
323 gastrointestinal disorders (4.7%; **Table S12**). Five (11.6%) patients experienced 6 SAEs  
324 of abscess requiring a hospital admission or ER visit for incision and drainage. These  
325 events resolved and patients continued garetosmab after a temporary interruption of  
326 study drug; 5 of these 6 SAEs were deemed related to garetosmab by the investigator.

327 In order to determine if epistaxis events were related to changes in BMP/TGF $\beta$   
328 family members other than activin A known to regulate angiogenesis and vascular  
329 endothelium homeostasis, levels of BMP9 were measured.<sup>24,25</sup> Minor fluctuations in  
330 serum BMP-9 were observed in both the placebo and in the garetosmab treatment  
331 group. The onset of epistaxis occurred in patients with stable and fluctuating serum  
332 BMP-9 concentrations. (**Figure S8**).



DiRocco LUMINA1 ms

333 The percentage of patients with infusion reactions was balanced between  
334 garetosmab (5/20 [25%]) and placebo (6/24 [25%]). Except for two infusion reactions of  
335 moderate severity that occurred in patients who received garetosmab during Period\_1,  
336 the other infusion reactions were reported as mild. Some reactions required a temporary  
337 infusion interruption or antihistamine (loratadine) pre-medication (n=2), but all infusions  
338 were completed. No patient discontinued treatment due to infusion reactions and none  
339 of the infusion reactions were associated with signs or symptoms of anaphylaxis or  
340 development of antidrug antibodies.

341 There were five deaths (5/44; 11.4%) during the study, all of which occurred in  
342 Period\_2 (Open label) or in the open label extension between 8-16 (median-15) doses  
343 of garetosmab; none occurred during the double-blind period (Period\_1). The deaths  
344 were reported by investigators as unrelated to garetosmab. The case summaries can be  
345 found in Supplement **Table S13**. As can be seen in **Figure 3B and 3D**, there was no  
346 relationship between subjects who died and the frequency or severity of epistaxis. The  
347 causes of death were head and brain trauma due to a fall in the setting of severe motor  
348 disability; hemorrhagic stroke in the setting of poorly controlled hypertension and  
349 previous strokes; fatal intestinal obstruction in the setting of a previous episode of  
350 intestinal obstruction; cardiac arrest during surgery procedure for traumatic spleen  
351 rupture due to fall; sudden cardiac death in a patient with lung granulomatous  
352 inflammation most likely attributable to chronic pulmonary aspiration.

353 Of the five deaths, three patients had a CAJIS score  $\geq 24$  and either profound or  
354 end-of-life disease severity as measured by the clinical staging of FOP developed by  
355 Pignolo & Kaplan.<sup>14</sup> Among the fatal events in study participants with lower CAJIS

DiRocco LUMINA1 ms

356 scores, one occurred in a 26 to 30-year-old patient with a CAJIS score of 16 (moderate  
357 disease staging) who died from a fall resulting in severe head and brain trauma. This  
358 individual had significant rigidity and walking disability at baseline. Another was a 36 to  
359 40-year-old patient with a CAJIS score of 19 (severe disease staging) who died from  
360 apparent sudden cardiac arrest with extensive granulomatous formation in the lungs  
361 consistent with chronic aspiration of foreign material.

DiRocco LUMINA1 ms

## 362 **Discussion**

363 This phase 2 study was conducted to assess the safety and efficacy of garetosmab in  
364 patients with FOP. The initial hypothesis for Period\_1 was that garetosmab prevents  
365 formation of new lesions and progression of pre-existing lesions. This was based on  
366 preclinical data demonstrating that activin A is required for the formation of new  
367 heterotopic bone lesions, as well as continued growth and expansion of pre-existing, yet  
368 nascent lesions.<sup>17,18</sup> Data from Period\_1 demonstrated that the most pronounced effect  
369 of garetosmab was the suppression of the formation of new HO lesions. Garetosmab  
370 did not significantly affect the continued growth and expansion of pre-existing HO  
371 lesions. Contrary to our apriori hypothesis, these established lesions had already  
372 achieved maturity prior to the administration of garetosmab as evidenced by no  
373 significant growth in the placebo arm (**Table S14**). This finding led to prospective  
374 redefining of the study hypothesis for Period\_2 to be that garetosmab prevents  
375 formation of new HO lesions in patients switching from placebo to garetosmab. The  
376 hypothesis was agreed upon with the US Food and Drug Administration, along with  
377 concordance that patients exposed to placebo during Period\_1 could serve as the  
378 control group when they transitioned to receive garetosmab during Period\_2 given the  
379 ultra-rare nature of FOP and striking results in Period\_1. Notably, no new lesions were  
380 detected in Period\_2 by CT in patients transitioning to garetosmab, while efficacy  
381 persisted in those who received garetosmab during Period\_1 and continued  
382 garetosmab in Period\_2. This study also demonstrated that PET and CT scans were  
383 similarly well correlated in the detection of new lesions.

DiRocco LUMINA1 ms

384 In addition to the significant reduction in the number of new HO lesions, treatment  
385 with garetosmab demonstrated a significant effect on the incidence and frequency of  
386 soft-tissue inflammatory flare-ups based upon both patient diary and investigator  
387 adverse event reporting. Flare-ups are a significant burden for patients with FOP, often  
388 are painful and debilitating and require the use of corticosteroids in high doses or during  
389 prolonged periods of time. The reduction in flare ups by garetosmab suggests that flare-  
390 ups are also associated with the activin A pathway and highlights an additional potential  
391 utility of garetosmab as a disease-modifying and steroid-sparing treatment for patients  
392 with FOP.

393 Data from patients treated with garetosmab in both Period\_1 and Period\_2 highlight  
394 the durability of garetosmab in preventing the formation of new HO lesions, as evident  
395 from both CT and PET scan results. This effect by garetosmab was sustained through  
396 week 76.

397 The clinical program for garetosmab included two previous phase 1 first-in-human  
398 studies conducted in healthy volunteers (Clinicaltrials.gov: NCT02870400,  
399 NCT02943239) that showed garetosmab in multiple doses up to 10 mg/kg (single dose)  
400 and 10 mg/kg Q4W for 4 doses were well-tolerated. In one study of 30 healthy females  
401 treated with garetosmab and 10 randomized to placebo, there were no occurrences of  
402 epistaxis or skin and soft tissue infections, suggesting that these effects of garetosmab  
403 maybe specific to FOP.<sup>23</sup> In another phase 1 study (NCT02943239) combining  
404 garetosmab with an anti-myostatin, GDF8 mAb (n=82), there was a single epistaxis  
405 event and 2 episodes of postmenopausal bleeding events. Overall there were 3 (3.75%)  
406 bleeding event AEs (1 epistaxis and 2 episodes of postmenopausal bleeding) amongst

DiRocco LUMINA1 ms

407 122 volunteers which were all non-serious and mild in severity. The review of the  
408 healthy volunteer data from Phase I clinical trials did not suggest a signal between  
409 garetosmab and epistaxis although the exposure to garetosmab was brief.

410 Overall, in this study, the AEs were predominantly mild in severity, with no effect on  
411 patients' ability to receive garetosmab. Notable AE imbalances with garetosmab during  
412 Period\_1 included epistaxis, madarosis, and a composite of skin and soft tissue  
413 infections (which included skin abscesses, folliculitis, cellulitis, furuncles and  
414 carbuncles). Based on results from Period\_1, higher incidences of epistaxis, madarosis,  
415 and skin and soft tissue infections were determined to be associated with garetosmab.

416 Further investigation shows that while there was an apparent link between  
417 garetosmab and epistaxis, there is no apparent link between garetosmab and bleeding  
418 events in other organs or systems; these events were balanced during Period\_1. The  
419 great majority of epistaxis events throughout the study were mild in severity, with only 4  
420 moderate events and one severe event. The biological mechanism behind inhibition of  
421 activin A with garetosmab and the occurrence of epistaxis in a subset of FOP patients is  
422 not understood. While activin A utilizes the same type II receptors as BMP9, which is  
423 associated with angiogenesis and vascular endothelium homeostasis,<sup>24,25</sup> treatment-  
424 related changes or epistaxis events did not correlate with fluctuations in serum BMP-9  
425 levels. Furthermore, there was no difference in serum BMP9 levels among patients with  
426 a fatal outcome. Coagulation tests and platelet functional assays were also in the  
427 normal ranges. Based on available data, no abnormalities were reported suggesting  
428 that the patients enrolled did not have coagulation defects at study entry or post  
429 garetosmab treatment.

DiRocco LUMINA1 ms

430 Five fatal events were observed during Period\_2 and subsequent open-label  
431 extension; in both periods patients received only garetosmab. Three of the 5 patients  
432 who died experienced epistaxis and all events were mild to moderate in severity. Two of  
433 these patients experienced one event (one of them had history of epistaxis prior to  
434 study enrollment, and the other had medical history of brain cavernoma hemorrhage as  
435 well as pigmented purpuric dermatosis, which is an inflammatory dermatitis with  
436 vascular fragility); the third patient reported 2 epistaxis events (**Figure 3B**).

437 Of the five fatalities, two of the deaths were due to complications resulting from falls,  
438 which is common in patients with FOP. One death was due to intestinal obstruction  
439 which has been previously reported as a complication of FOP.<sup>15</sup> One death occurred as  
440 a result of a hemorrhagic stroke to the deep structures of the brain leading to acute  
441 respiratory failure. This patient presented with difficult-to-control arterial hypertension  
442 and interpretation of the brain CT by two independent neuroradiologists concluded  
443 evidence of chronic hypertensive effects and the findings suggested death was likely a  
444 consequence of hypertension. One death was initially considered to be related to a  
445 hemorrhagic event in the lung, which generated concern around the possible  
446 association between bleeding and deaths, given that early in the course of the study  
447 epistaxis had already been identified as a risk associated with garetosmab. As a result,  
448 a temporary pause in patient dosing was instituted to allow the sponsor time to conduct  
449 thorough investigations into the deaths, evaluate the autopsy reports performed in 2 of  
450 the 5 patients with a fatal outcome, and further assess a potential association between  
451 garetosmab and bleeding risk. The cause of death of the patient initially thought to have  
452 experienced lung hemorrhage was ultimately determined to be sudden cardiac arrest

DiRocco LUMINA1 ms

453 secondary to recurrent aspiration. There was no evidence of any bleeding which was  
454 further confirmed by a second independent autopsy report from a pathologist at a  
455 separate institution.

456 While there are published reports of mortality in FOP, there are no published  
457 reports of annualized rates of death in this community.<sup>13</sup> With this in mind, post-hoc  
458 assessment of safety data by all the authors concluded: 1) While epistaxis events were  
459 related to garetosmab 2) there was no apparent association between epistaxis and  
460 patient deaths; 3) causes of death appeared consistent with known causes of death and  
461 life expectancy for patients with FOP of similar age and disease severity as measured  
462 by clinical staging.<sup>15</sup> Four of the 5 patients who died on study had advanced CAJIS  
463 scores. The one relatively young patient with a lower CAJIS score was known to have  
464 significant gait difficulties due to FOP, and died from a fall down a flight of stairs not  
465 believed to be precipitated by an antecedent bleed. Garetosmab was considered  
466 unlikely to be the cause of death in these cases, which appeared more likely to have  
467 been related to the underlying severity of their FOP disease. Although a definitive link to  
468 garetosmab could not be established in this population with advanced disease, the  
469 number of deaths was relatively high for this small study. As these deaths were in the  
470 open label period, although a contribution by the drug can not be excluded, no common  
471 pathogenetic mechanism of deaths related to garetosmab has been identified.

472 The major impact of garetosmab in reducing new HO suggests that the greatest  
473 utility of garetosmab may be early in the disease course before substantial HO has  
474 occurred and before permanent disability ensues. Together with previously published  
475 preclinical data in murine models of FOP, these data indicate that activin A is also

DiRocco LUMINA1 ms

476 required for the continued growth and progression of new lesions. The reduction in  
477 flare-ups provides an additional and important benefit by significantly reducing disease  
478 burden. Together, the data generated during LUMINA-1 demonstrate that activin A is a  
479 required ligand for HO in FOP, and provides strong evidence that inhibition of activin A  
480 using garetosmab is a promising disease-modifying therapy with the ability to not only  
481 block HO but also reduce the number and severity of flare-ups. In the context of this  
482 ultra-rare disease setting, the patient population was small with limited patient exposure.  
483 A phase 3 adult study and a pediatric study are planned to continue to assess the  
484 benefits and risks of garetosmab intervention in people with FOP, and further validate  
485 the results from this small phase 2 study.



DiRocco LUMINA1 ms

## 486 **Conclusions**

487 Garetosmab treatment has demonstrated substantial and persistent reduction of new  
488 heterotopic bone lesion formation and flare-ups in adults with FOP. Although a definitive  
489 link between garetosmab and the five deaths was not established in this population with  
490 advanced disease, the number of deaths was relatively high for this small study,  
491 therefore the benefit-risk of garetosmab will be further evaluated in Phase 3 clinical  
492 studies. Garetosmab may provide a therapeutic option in this ultra-rare, severely  
493 debilitating, life-threatening disease and further studies are planned.

494

DiRocco LUMINA1 ms

495 **Consortium Author Information**

496 **Authors and Affiliations**

497 **Department of Pediatrics, Unit of Rare Diseases, IRCCS Istituto Giannina Gaslini,**

498 **Genoa, Italy**

499 Maja Di Rocco, Annalisa Madeo

500 **Regeneron Pharmaceuticals, Tarrytown, NY, USA**

501 Eduardo Forleo-Neto, Cynthia Portal-Celhay, Neena Sarkar, Peijie Hou, Bret Musser,

502 Anita Boyapati, Kusha Mohammadi, Scott Mellis, Andrew J. Rankin, Aris N.

503 Economides, Dinko Gonzalez Trotter, Gary Herman, Sarah J. O'Meara, Richard

504 DelGizzi, David M. Weinreich, George D. Yancopoulos

505 **Department of Medicine, Mayo Clinic, Rochester, MN, USA**

506 Robert Pignolo

507 **Centre for Metabolic Bone Disease Royal National Orthopaedic Hospital NHS**

508 **Trust, London, UK**

509 Richard Keen, Judith S Bubbear

510 **Department of Rheumatology- DMU Locomotion, Assistance Publique - Hôpitaux**

511 **de Paris, Paris, France**

512 Philippe Orcel, Thomas Funck-Brentano

DiRocco LUMINA1 ms

513 **INSERM Université Paris Cité, Paris, France**

514 Philippe Orcel, Thomas Funck-Brentano

515 **Department of Rheumatology, Cochin Hospital, Assistance Publique - Hôpitaux**  
516 **de Paris, Paris, France**

517 Christian Roux, Sami Kolta

518 **Institute of Medical Sciences, Medical College of Rzeszów University, Rzeszów**  
519 **University, Rzeszów, Podkarpackie, Poland**

520 Jacek Tabarkiewicz, Małgorzata Szczepanek

521 **Department of Rheumatology, Hospital Universitario Ramón y Cajal, Madrid,**  
522 **Spain**

523 Javier Bachiller-Corral

524 **University Health Network, University of Toronto, Toronto, ON, Canada**

525 Angela M Cheung, Lianne Tile

526 **Vanderbilt University Medical Center, Program for Metabolic Bone Disorders,**  
527 **Nashville, TN, USA**

528 Kathryn M Dahir

529 **Department of Internal Medicine Section of Endocrinology, Amsterdam UMC, Vrije**  
530 **Universiteit, Amsterdam Bone Center, Amsterdam, The Netherlands**

DiRocco LUMINA1 ms

531 Esmée Botman, E. Marelise W. Eekhoff

532 **Department of Radiology and Nuclear Medicine , Amsterdam UMC, Vrije**

533 **Universiteit, Amsterdam, The Netherlands**

534 Pieter G Raijmakers

535 **Departments of Orthopaedics, Medicine and the Center for Research in FOP &**

536 **Related Disorders, University of Pennsylvania Perelman School of Medicine,**

537 **Philadelphia, PA, USA**

538 Mona Al Mukaddam, Frederick S. Kaplan

539

540 **Disclosures**

541 Maja Di Rocco: PI of Regeneron Pharmaceuticals Inc. and Ipsen trials.

542 Eduardo Forleo-Neto: employee of and holds stocks and shares in Regeneron

543 Pharmaceuticals Inc.

544 Robert J. Pignolo: PI of the Regeneron Pharmaceuticals Inc. LUMINA-1 and

545 Clementia/Ipsen MOVE trials, founding member and immediate past president of the

546 International Clinical Council (ICC) on FOP, and chair of the ICC Publications

547 Committee.

DiRocco LUMINA1 ms

- 548 Richard Keen: PI of clinical trials sponsored by Clementia/Ipsen and Regeneron  
549 Pharmaceuticals Inc; non-paid member of the International Clinical Council on FOP and  
550 IFOPA registry advisory board.
- 551 Philippe Orcel: PI of clinical trial sponsored by Regeneron Pharmaceuticals Inc.
- 552 Thomas Funck-Brentano: is a sub-investigator of the Regeneron Pharmaceuticals Inc.  
553 LUMINA-1 trial and PI of IPSEN FALKON trial
- 554 Christian Roux: research grants, for the institution, from Regeneron Pharmaceuticals  
555 Inc.
- 556 Sami Kolta: sub-investigator of the Regeneron Pharmaceuticals Inc. LUMINA-1 trial.
- 557 Annalisa Madeo: sub-Investigator in clinical trials sponsored by Regeneron  
558 Pharmaceuticals Inc. and Clementia-Ipsen.
- 559 Judith S. Bubbear: sub-investigator of the Regeneron Pharmaceuticals Inc. LUMINA-1  
560 and Clementia/Ipsen MOVE trials.
- 561 Jacek Tabarkiewicz: grants to institution (UR), speaker for Merck, Novartis; hired  
562 scientific expert for SoftSystem.
- 563 Małgorzata Szczepanek: speaker for Roche.
- 564 Javier Bachiller-Corral: investigator of clinical trial sponsored by Regeneron  
565 Pharmaceuticals Inc.
- 566 Angela M. Cheung: grant to institution (UHN) for clinical trial, no personal COI.

DiRocco LUMINA1 ms

567 Kathryn M. Dahir: PI on the Regeneron Pharmaceuticals Inc. Trial. This project  
568 described was supported by CTSA award No. UL1 TR002243 from the National Center  
569 for Advancing Translational Sciences. Its contents are solely the responsibility of the  
570 authors/sponsor and do not necessarily represent official views of the National Center  
571 for Advancing Translational Sciences or the National Institutes of Health.

572 Esmée Botman: is a sub-investigator of the Regeneron Pharmaceuticals Inc. LUMINA-1  
573 trial at the Amsterdam UMC, the Netherlands.

574 Pieter G Raijmakers: is a sub-investigator of the Regeneron Pharmaceuticals Inc.  
575 LUMINA-1 trial at the Amsterdam UMC, the Netherlands.

576 Mona Al Mukaddam: PI of clinical trials sponsored by Clementia/Ipsen, Regeneron  
577 Pharmaceuticals Inc. and Incyte; non-paid member of the International Clinical Council  
578 on FOP and IFOPA registry advisory board.

579 Lianne Tile: grant to institution (UHN) for clinical trial (sub-investigator), no personal  
580 COI.

581 Cynthia Portal-Celhay: employee of and holds stocks and shares in Regeneron  
582 Pharmaceuticals Inc.

583 Melissa Simek-Lemos: employee of and holds stocks and shares in Regeneron  
584 Pharmaceuticals Inc.

585 Neena Sarkar: employee of and holds stocks and shares in Regeneron  
586 Pharmaceuticals Inc.

DiRocco LUMINA1 ms

587 Peijie Hou: employee of and holds stocks and shares in Regeneron Pharmaceuticals

588 Inc.

589 Bret Musser: employee of and holds stocks and shares in Regeneron Pharmaceuticals

590 Inc.

591 Anita Boyapati: employee of and holds stocks and shares in Regeneron

592 Pharmaceuticals Inc.

593 Scott Mellis: employee of and holds stocks and shares in Regeneron Pharmaceuticals

594 Inc.

595 Andrew J. Rankin: employee of and holds stocks and shares in Regeneron

596 Pharmaceuticals Inc.

597 Aris N. Economides: employee of and holds stocks and shares in Regeneron

598 Pharmaceuticals Inc.

599 Dinko Gonzalez Trotter: employee of and holds stocks and shares in Regeneron

600 Pharmaceuticals Inc.

601 Gary Herman: employee of and holds stocks and shares in Regeneron Pharmaceuticals

602 Inc.

603 David M. Weinreich: employee of and holds stocks and shares in Regeneron

604 Pharmaceuticals Inc.

605 George D. Yancopolous: employee of and holds stocks and shares in Regeneron

606 Pharmaceuticals Inc.

DiRocco LUMINA1 ms

607 E. Marelise W. Eekhoff: subsidies/financing FOP research: Dutch FOP Patient  
608 Foundation, IFOPA, Regeneron Pharmaceuticals Inc., EU-IMI (AZ), Clementia/Ipsen  
609 (i.e., general lecture). Non-paid Board memberships: the International Clinical Council  
610 on FOP, IFOPA registry advisory board, Dutch Society for Endocrinology (NVE) BoNe;  
611 Representative: Amsterdam Bone Center and Rare Bone Expert Center, European FOP  
612 consortium. Member of ERN BOND and of an ASBMR committee.

613 Frederick S. Kaplan: founding member and past president of the International Clinical  
614 Council on FOP, member of the Medical Advisory Board of the IFOPA Global Registry  
615 and global principal investigator on the Regeneron LUMINA-1 and the Clementia/Ipsen  
616 MOVE trials.



DiRocco LUMINA1 ms

## 617 **Acknowledgements**

618 We thank the patients and their families for their participation in this study and the  
619 healthcare professionals and investigators who treated these patients and made this  
620 study possible.

621 We acknowledge the contributions of Kevin Niswender, MD, PhD; Edward Sherwood.  
622 MD; Lana Howard, BSN,RN, CCRP; Margo Black, MSN, RN, CCRP, at Vanderbilt  
623 University Medical Center.

624 We acknowledge the contributions of Staci Kallish DO, Katherine S.Toder CCRC, and  
625 Renee Jurek CRC at the University of Pennsylvania.

626 We thank Donal O'Donovan Ph.D. for the safety figure concept and Richa Attre Ph.D.  
627 from Regeneron Pharmaceuticals, Inc. for assistance with development of the  
628 manuscript. Medical writing support under the direction of the authors was provided by  
629 Caroline Ridley, PhD, Prime Global (Knutsford, UK) according to Good Publication  
630 Practice guidelines ([Link](#)) and funded by Regeneron Pharmaceuticals, Inc.

631 The authors were involved in the study design and collection, analysis, and  
632 interpretation of data. All authors had full access to all the data in this study and take  
633 complete responsibility for the integrity of the data and the accuracy of the data  
634 analysis.

## 635 **Data-sharing statement**

636 Qualified researchers may request access to study documents that support the methods  
637 and findings reported in this manuscript. Individual anonymized patient data will be

DiRocco LUMINA1 ms

638 considered for sharing once the product and indication has been approved by major  
639 health authorities (eg, FDA, EMA, PMDA, etc), if there is legal authority to share the  
640 data and there is not a reasonable likelihood of patient re-identification. Submit requests  
641 to <https://vivli.org/>.

642

## 643 **References**

- 644  
645 1. Pignolo, R.J., Shore, E.M. & Kaplan, F.S. Fibrodysplasia ossificans progressiva:  
646 clinical and genetic aspects. *Orphanet J Rare Dis* **6**, 80 (2011).
- 647 2. Baujat, G. et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in  
648 France: an estimate based on a record linkage of two national databases.  
649 *Orphanet J Rare Dis* **12**, 123 (2017).
- 650 3. Liljestrom, M., Pignolo, R.J. & Kaplan, F.S. Epidemiology of the Global  
651 Fibrodysplasia Ossificans Progressiva (FOP) Community. *Journal of Rare*  
652 *Diseases Research & Treatment* **5**, 31-36 (2020).
- 653 4. Morales-Piga, A. et al. Fibrodysplasia ossificans progressiva in Spain:  
654 epidemiological, clinical, and genetic aspects. *Bone* **51**, 748-755 (2012).
- 655 5. Pignolo, R.J. et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in  
656 the United States: estimate from three treatment centers and a patient  
657 organization. *Orphanet Journal of Rare Diseases* **16**, 350 (2021).
- 658 6. Pignolo, R.J. et al. Natural history of fibrodysplasia ossificans progressiva: cross-  
659 sectional analysis of annotated baseline phenotypes. *Orphanet J Rare Dis* **14**, 98  
660 (2019).
- 661 7. Pignolo, R.J. et al. The natural history of flare-ups in fibrodysplasia ossificans  
662 progressiva (FOP): a comprehensive global assessment. *J Bone Miner Res* **31**,  
663 650-656 (2016).
- 664 8. Peng, K. et al. Longitudinal evaluation of pain, flare-up, and emotional health in  
665 fibrodysplasia ossificans progressiva: analyses of the International FOP Registry.  
666 *JBMR Plus* **3**, e10181-e10181 (2019).

DiRocco LUMINA1 ms

- 667 9. Kaplan, F.S. et al. Fibrodysplasia ossificans progressiva. *Best practice &*  
668 *research. Clinical rheumatology* **22**, 191-205 (2008).
- 669 10. Ortiz-Agapito, F. & Colmenares-Bonilla, D. Quality of life of patients with  
670 fibrodysplasia ossificans progressiva. *J Child Orthop* **9**, 489-493 (2015).
- 671 11. Cohen, R.B. et al. The natural history of heterotopic ossification in patients who  
672 have fibrodysplasia ossificans progressiva. A study of forty-four patients. *J Bone*  
673 *Joint Surg Am* **75**, 215-219 (1993).
- 674 12. Liu, J.X., Hu, R., Sun, Y. & Jiang, H. General anesthesia in fibrodysplasia  
675 ossificans progressive: a case report and clinical review. *Int J Clin Exp Med* **7**,  
676 1474-1479 (2014).
- 677 13. Kaplan, F.S., Al Mukaddam, M. & Pignolo, R.J. A cumulative analogue joint  
678 involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP). *Bone*  
679 **101**, 123-128 (2017).
- 680 14. Pignolo, R.J. & Kaplan, F.S. Clinical staging of Fibrodysplasia Ossificans  
681 Progressiva (FOP). *Bone* **109**, 111-114 (2018).
- 682 15. Kaplan, F.S. et al. Early mortality and cardiorespiratory failure in patients with  
683 fibrodysplasia ossificans progressiva. *J Bone Joint Surg Am* **92**, 686-691 (2010).
- 684 16. Shore, E.M. et al. A recurrent mutation in the BMP type I receptor ACVR1 causes  
685 inherited and sporadic fibrodysplasia ossificans progressiva. *Nat Genet* **38**, 525-  
686 527 (2006).
- 687 17. Hatsell, S.J. et al. ACVR1R206H receptor mutation causes fibrodysplasia  
688 ossificans progressiva by imparting responsiveness to activin A. *Sci Transl Med*  
689 **7**, 303ra137 (2015).

DiRocco LUMINA1 ms

- 690 18. Upadhyay, J. et al. The expansion of heterotopic bone in fibrodysplasia  
691 ossificans progressiva is Activin A-dependent. *J Bone Miner Res* **32**, 2489-2499  
692 (2017).
- 693 19. Alessi Wolken, D.M. et al. The obligatory role of Activin A in the formation of  
694 heterotopic bone in Fibrodysplasia Ossificans Progressiva. *Bone* **109**, 210-217  
695 (2018).
- 696 20. Hino, K. et al. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.  
697 *Proc Natl Acad Sci U S A* **112**, 15438-15443 (2015).
- 698 21. Aykul, S. et al. Activin A forms a non-signaling complex with ACVR1 and type II  
699 Activin/BMP receptors via its finger 2 tip loop. *eLife* **9**, e54582 (2020).
- 700 22. Kenny, L.M. et al. Reproducibility of [11C]choline-positron emission tomography  
701 and effect of trastuzumab. *Clinical cancer research : an official journal of the*  
702 *American Association for Cancer Research* **16**, 4236-4245 (2010).
- 703 23. Vanhoutte, F. et al. Pharmacokinetics and Pharmacodynamics of Garetosmab  
704 (Anti-Activin A): Results From a First-in-Human Phase 1 Study. *J Clin Pharmacol*  
705 **60**, 1424-1431 (2020).
- 706 24. Robert, F. et al. Future treatments for hereditary hemorrhagic telangiectasia.  
707 *Orphanet J Rare Dis* **15**, 4 (2020).
- 708 25. Wooderchak-Donahue, W.L. et al. BMP9 mutations cause a vascular-anomaly  
709 syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia.  
710 *Am J Hum Genet* **93**, 530-537 (2013).

711

712 **Figures and Tables**

713 **Table 1. Percent of patients with flare-ups by patient diary and by investigator**

714 **adverse event (AE) verbatim term in (A) Period\_1 and (B) Period\_2 (mITT)**

<b>Incidence of flare-up events</b>			
<b>A</b>			
<b>Double-blind Period_1 (P1)* Inter-group comparison – n (%)</b>			
<b>Patient diary</b>	<b>Placebo (n=24)</b>	<b>Garetosmab (n=20)</b>	<b>P value</b>
	17 (70.8)	7 (35.0)	0.03
<b>Investigator AE verbatim term</b>	10 (41.7)	2 (10.0)	0.04
<b>B</b>			
<b>Period_2 (P2) compared to Period_1 (P1)** Intra-group comparison – n (%)</b>			
	<b>Placebo (P1) vs Garetosmab (P2) (n=22)#</b>		<b>P value</b>
<b>Patient diary</b>	15 (68.2)	3 (13.6)	0.0005
<b>Investigator AE verbatim term</b>	10 (45.5)	3 (13.6)	0.019

715 \*Active HO analysis set; \*\* mITT analysis set; #No comparison performed since the intent is to evaluate persistency of

716 garetosmab effect. mITT=modified intent-to-treat. \*Of the 24 patients on placebo in Period\_1, 22 went on to

717 garetosmab in Period\_2. Shown here are only those 22 patients who transitioned from placebo to garetosmab.

718

719 **Table 2. Summary of TEAEs during the double-blind period of the study**

720 **(Period\_1)\***


<b>Patients, n (%)</b>	<b>Placebo (n=24)</b>	<b>Garetosmab 10 mg/kg Q4W (n=20)</b>
≥1 TEAE	24 (100)	20 (100)
≥1 SAE	2 (8.3)	4 (20.0)
≥1 severe TEAE	3 (12.5)	3 (15.0)
≥1 drug-related TEAE	13 (54.2)	13 (65.0)
≥1 TEAE resulting in discontinuation from study	0	1 (5.0)
≥1 TEAE resulting in death	0	0
≥1 TEAE of AESI†	0	1 (5.0)
TEAEs occurring in ≥4 patients in any treatment group□		
Headache	7 (29.2)	10 (50.0)
Epistaxis	4 (16.7)	10 (50.0)
Acne	3 (12.5)	6 (30.0)
Pain in extremity	9 (37.5)	5 (25.0)
Arthralgia	9 (37.5)	7 (35.0)
Diarrhea	6 (25.0)	5 (25.0)
Madarosis	0	6 (30)
Back pain	1 (4.2)	4 (20.0)
Neck pain	3 (12.5%)	4 (20.0%)
Toothache	0	4 (20.0)
Neck pain	3 (12.5)	4 (20.0)
Rhinitis	0	4 (20.0)
Dizziness	2 (8.3%)	4 (20.0%)
Nasopharyngitis	5 (20.8)	3 (15.0)
Rash	4 (16.7)	2 (10.0)

721 AESI=adverse event of special interest; Q4W=every 4 weeks; SAE=serious adverse event;  
 722 TEAE=treatment-emergent adverse event. \*Safety analysis set. †AESI included epididymitis, orchitis,  
 723 hydrocele, scrotum pain, scrotum swelling, moderate to severe episodes of non-traumatic bleeding,


724 moderate epistaxis ( $\geq 30$  minutes or requiring professional medical intervention), and severe epistaxis  
725 (based on the definition of a severe TEAE).  Preferred term.



726 **Figure 1. Effect of garetosmab on the (A) change from baseline in TLA compared**  
727 **with placebo, (B) total number of new HO lesions assessed by quantitative**  
728 **imaging, and (C) total volume of new HO lesions by CT per patient in Period\_1**




729



730

731

732 **C.**




733

734 **(A)** Time-weighted average of the percent change from baseline in total lesion activity as assessed by  
735  $^{18}\text{F}$ -NaF PET over 28 weeks (active HO analysis set). **(B)** Total number of new lesions in all patients per  
736 group (combined) by CT and  $^{18}\text{F}$ -NaF PET during Period\_1 relative to baseline (active HO analysis set).  
737 **(C)** Total volume of new lesions per patient as assessed by CT in Period\_1 (active HO analysis set).  $^{18}\text{F}$ -  
738 NaF PET=fluorine-18-labelled sodium fluoride positron emission tomography; HO=heterotopic  
739 ossification; IV=intravenous; LS=least squares; Q4W=every 4 weeks; SE=standard error; TLA=total  
740 lesion activity; TWA=time-weighted average.

741

742 **Figure 2. Effect of garetosmab in Period\_2 relative to Period\_1 on the (A, B) total**  
743 **number of new HO lesions, (C) mean total volume of new HO lesions (D) TLA in**  
744 **new HO lesions, and (E, F) percent of patients with new lesions assessed by**  
745 **quantitative imaging in patients originally randomized to placebo**




746  
747 **(A)** Total number of new lesions by CT during Period\_2 relative to Period\_1 (mITT analysis set). **(B)** Total  
748 number of new lesions by <sup>18</sup>F-NaF PET during Period\_2 relative to Period\_1 (mITT analysis set). **(C)**

749 Mean total volume of new lesions as assessed by CT in Period\_2 relative to Period\_1 (mITT analysis  
750 set). **(D)** TLA of new lesions by <sup>18</sup>F-NaF PET in Period\_2 relative to Period\_1 (mITT analysis set). **(E)**  
751 Percent of patients with new lesions by CT during Period\_2 relative to Period\_1 (mITT analysis set). **(F)**  
752 Percent of patients with new lesions by <sup>18</sup>F-NaF PET during Period\_2 relative to Period\_1 (mITT analysis  
753 set). <sup>18</sup>F-NaF PET=fluorine-18-labelled sodium fluoride positron emission tomography; CT=computed  
754 tomography; HO=heterotopic ossification; mITT=modified intent-to-treat; TLA=total lesion activity.  
755 A new flare-up was defined as a flare-up event starting in the corresponding period. Investigator-defined  
756 flare-ups were defined as TEAEs with the verbatim term containing “flare”. HO=heterotopic ossification;  
757 mITT=modified intent-to-treat; TEAE=treatment-emergent adverse event.

758 Figure 3 (A) Relationship between patient baseline age and disease severity as measured by the clinical staging  
759 of FOP (B) Lack of association of epistaxis events and deaths in LUMINA-1 study (C) madarosis events in the  
760 LUMINA-1 study (D) number of epistaxis TEAEs in patients with or without fatal SAE.


761 A. Age vs Disease severity



762


763 \*Cumulative Analog Joint Involvement Scale (CAJIS). CAJIS is an assessment of mobility limitation at 15 anatomic locations; scores are tabulated  
764 for each site as normal unaffected (0), affected (1), or completely functionally ankylosed (2). The total score ranges from 0 to 30. On the basis of  
765 FOP features (flare-up activity, body regions affected, thoracic insufficiency syndrome, other complications) and its consequences (impairments in  
766 activities of daily living [ADLs] and ambulation, increasing CAJIS), five clinical stages of disease severity have been defined.<sup>14</sup> In early-stage FOP  
767 the total CAJIS score is usually  $\leq 4$ , in moderate stage 5-18, severe stage 19-24, profound  $\geq 24$ , and end of life stage  $\geq 28$ .

768 **B. Epistaxis events and deaths**



769

770 C. Madarosis events



771





772 **D. Epistaxis events**

	Death	No Death	Total
Number of Epistaxis events	(N=5)	(N=39)	(N=44)
0	2 (40.0%)	19 (48.7%)	21 (47.7%)
1	2 (40.0%)	1 (2.6%)	3 (6.8%)
2	1 (20.0%)	6 (15.4%)	7 (15.9%)
>=3	0	13 (33.3%)	13 (29.5%)

773

774 **(A)** Red triangles indicate patients with fatal SAEs. **(B)** In red are patients that received placebo during the 28-week Period\_1, and in blue  
 775 patients receiving garetosmab. Dots represent epistaxis events. Black dots are mild epistaxis events, yellow moderate (defined as any episode  
 776 lasting longer than 30 minutes or requiring medical intervention) and red is severe. Red arrows indicate the patient experienced a fatal SAE.  
 777 **(C)** In red are patients that received placebo during the 28-week Period\_1, and in blue patients receiving garetosmab. Dots represent  
 778 madarosis events. Black dots are mild madarosis events, yellow moderate. Red arrows indicate the patient experienced a fatal SAE. **(D)** The  
 779 table shows the number of epistaxis TEAEs in patients with or without fatal SAE. No drug refers to period after dosing was discontinued  
 780 following Clinical hold. CAJIS=Cumulative Analog Joint Involvement Scale; SAE=severe adverse event; TEAE=treatment-emergent adverse  
 781 event.

782

**a****b****c**